4 results about "Overactive bladder" patented technology

The invention discloses an application of a compound Darifenacin hydrobromide in preparation of a medicine for resisting influenza A (H1N1) virus, and belongs to the technical field of medicines. The invention discloses for the first time that Darifenacin hydrobromide can significantly inhibit replication of H1N1-PR8 virus, reduce virus titer and reduce cytopathic effect (CPE) in an in-vitro cell model, the EC50 value of Darifenacin hydrobromide is 2.5 [mu] M, and the selection index (SI) is gt; and 10, the compound has good antiviral activity and safety. The compound Darifenacin hydrobromide is a high-selectivity M3 muscarinic acetylcholine receptor antagonist and is approved to be used for treating overactive bladder at present, the invention discloses that the compound can inhibit replication and release of H1N1-PR8 virus for the first time, and the compound has a wide prospect of being developed into a medicine for treating human influenza virus infection.

The present invention provides improved methods for positioning of an implantable lead in a patient with an integrated EMG and stimulation clinician programmer. The integrated clinician programmer is coupled to the implantable lead, wherein the implantable lead comprises at least four electrodes, and to at least one EMG sensing electrode minimally invasively positioned on a skin surface or within the patient. The method comprises delivering a test stimulation at a stimulation amplitude level from the integrated clinician programmer to a nerve tissue of the patient with a principal electrode of the implantable lead. Test stimulations are delivered at a same stimulation amplitude level for a same period of time sequentially to each of the four electrodes of the implantable lead. A stimulation-induced EMG motor response is recorded with the integrated clinician programmer for each test stimulation on each electrode of the implantable lead via the at least one pair of EMG sensing electrodes so as to facilitate initial positioning of the implantable lead at a target stimulation region.

A neurostimulator is implantable into a body of a subject to treat an overactive bladder condition. The neurostimulator includes a pulse generator, circuitry, a lead, and a connector secured to the lead. The circuitry is disposed within the pulse generator and connected to a battery. The circuitry is configured to generate a stimulation signal with a duty cycle of between 0.1% and 2.5% and a total average current drain from the battery of between 0.1 μA and 5μA, the total average current drain including a background current, plus a stimulation current weighted by the duty cycle. The lead has an electrode assembly configured to direct the generated stimulation signal to tissue of the subject. The connector is adapted to allow the pulse generator to be detachable from and attachable to the lead.

The invention relates to multi-modal stimulation for treating tremor. A peripheral nerve stimulator is provided that stimulates the peripheral nerve to treat idiopathic tremor and other dyskinesia as well as overactive bladder, cardiac dysfunction, and neurotransmitter dysfunction. The peripheral nerve stimulator may be a non-invasive surface stimulator that provides multi-modal optimized therapy. The stimulation may be vibratory, electromechanical, thermal, radiant, electrical, magnetic, electromagnetic, optical, mechanical, chemical, thermal, ultrasonic, radio frequency (RF), acoustic, infrared, ultraviolet, X-ray, and / or microwave. Stimulation may be delivered using an open loop system and / or a closed loop system with feedback. Stimulation may be for one site or several sites.